Validation of the Japanese Version of the Functional Assessment of Cancer Therapy-Cognitive Function Version 3

Miyashita, Mika; Tsukamoto, Naoko; Hashimoto, Minoru; Kajiwara, Kohei; Kako, Jun; Okamura, Hitoshi

doi:10.1016/j.jpainsymman.2019.09.027

Cited by 7 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MMSE could not detect cognitive dysfunction in patients with breast cancer (Le Rhun et al, 2015). In general, cancer therapy-related cognitive impairment is subtle (Vardy et al, 2008); therefore, it is necessary to use a tool for evaluating the cognitive dysfunction related to cancer treatment, such as FACT-Cog (Miyashita et al, 2020), to assess their self-reported cognitive function.…”

Section: Discussionmentioning

confidence: 99%

Older patients’ experience of living with cognitive impairment related to hormone therapy for breast cancer: A qualitative study

Tenda

Miyashita

Yamada

et al. 2022

European Journal of Oncology Nursing

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Older patients’ experience of living with cognitive impairment related to hormone therapy for breast cancer: A qualitative study

Tenda

Miyashita

Yamada

et al. 2022

European Journal of Oncology Nursing

Self Cite

View full text Add to dashboard Cite

“…Thus, each user can opt for the version that best ts their purpose. Moreover, this validation study was conducted with non-CNS cancer patients, rather than with breast cancer patients only, as most studies previously did[e.g., [15][16][17], providing support to the robustness and stability of the instrument's multidimensional structure, which is transversal across various cultural contexts and cancer populations.…”

Section: Discussionmentioning

confidence: 99%

Validation study of the Functional Assessment of Cancer Therapy - Cognitive Function – Version 3 for the Portuguese population

Oliveira

Torres

Fernandes

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose: The purpose of this study was to evaluate the psychometric properties of the Functional Assessment of Cancer Therapy-Cognitive Function–Version 3 (FACT-Cog-v3) among non-central nervous system (CNS) cancer patients in Portugal. Methods: The validation study was conducted based on a convenience sample of 281 non-CNS cancer patients, aged between 18 and 65 years, recruited online. A confirmatory factor analysis (CFA) was used to test the factor structure of the Portuguese FACT-Cog-v3 version; internal consistency analysis was also conducted. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30–version 3) and the Hospital Anxiety and Depression Scale (HADS) were also used to test the concurrent, convergent, and discriminant validity of the scale.Results: CFA supported a four-factor model with good fix indexes and internal consistencies: perceived cognitive impairments (α=0.97), comments from others (α=0.92), perceived cognitive abilities (α=0.93), and impact on quality of life (α=0.92). Concurrent, convergent, and discriminant validities were confirmed. Moderate and strong correlations were found between the FACT-Cog-v3 subscales and the QLQ-C30 cognitive functioning subscale. Good convergent validity, with moderate correlations, was found between the FACT-Cog-v3 subscales and the HADS-A, HADS-D, and QLQ-C30 fatigue, sleep disturbance, and global health status subscales. There was acceptable discriminant validity, with weak and moderate correlations, between the FACT-Cog-v3 subscales and the QLQ-C30 pain and nausea/vomiting subscales.Conclusion: The Portuguese FACT-Cog-v3 version can be considered a reliable and valid measure to assess cognitive concerns of non-CNS cancer patients, with relevance for research and clinical practice.

show abstract

“…In general, cancer therapy-related cognitive impairment is subtle [24]. Therefore, it is necessary to use a tool for evaluating the cognitive dysfunction related to cancer treatment, such as FACT-Cog [25], to assess their self-reported cognitive function.…”

Section: Discussionmentioning

confidence: 99%

Older Patients’ Experience of Living With Cognitive Impairment Related to Hormone Therapy for Breast Cancer

Tenda

Miyashita

Yamada

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Purpose Patients with breast cancer may develop cognitive impairment as a result of hormone therapy and aging. This study aimed to describe older patients’ experience of cognitive impairment related to hormone therapy for breast cancer. Methods A qualitative and descriptive design was used. Semi-structured interviews were conducted for 11 patients to ask about their experience in daily life related to their cognitive impairment. Study participants were evaluated by cancer-specific geriatric assessment. Inductive content analysis was conducted using interview records. Results Three themes emerged from the patients’ narrative data: recognizing of cognitive impairments, impacts on mental health, and coping with cognitive impairments. Recognizing of cognitive function consisted of two categories: perception of cognitive changes and acknowledging their cognitive function status through interacting with others. Impacts on mental health consisted of six categories: decreased motivation for social activities, upset by perception of cognitive decline, concerns about impacts of cognitive impairment on treatment of breast cancer, concerns about care burden of their family, concerns about progressing of cognitive impairments, and feeling secure that their cognitive impairment is not unusual. Coping with cognitive impairments consisted of two categories: coping with problems related to cognitive impairment and trying to maintain and improve cognitive function. Conclusion Medical professionals should perform a comprehensive evaluation of older patients receiving hormone therapy for breast cancer.

show abstract

Validation of the Japanese Version of the Functional Assessment of Cancer Therapy-Cognitive Function Version 3

Cited by 7 publications

References 25 publications

Older patients’ experience of living with cognitive impairment related to hormone therapy for breast cancer: A qualitative study

Older patients’ experience of living with cognitive impairment related to hormone therapy for breast cancer: A qualitative study

Validation study of the Functional Assessment of Cancer Therapy - Cognitive Function – Version 3 for the Portuguese population

Older Patients’ Experience of Living With Cognitive Impairment Related to Hormone Therapy for Breast Cancer

Contact Info

Product

Resources

About